IMDQ-PEG-CHOL Adjuvant for Lymphatic Vaccine Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current recombinant protein vaccines for COVID-19 are poorly immunogenic and lack sufficient immune response, and existing TLR7/8 agonists like imidazoquinoline have rapid systemic dissemination causing unwanted immune activation, making them unsuitable for mass immunization campaigns.
Innovation Solution
Development of lipidated imidazoquinoline compounds, such as IMDQ-PEG-CHOL, which are conjugated to cholesteryl-poly(ethylene glycol) to enhance immune response by targeting lymphatic transportation and activating innate immune cells, thereby enhancing the immune response to antigens like SARS-CoV-2 spike protein.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If recombinant protein vaccines are used for COVID-19, then the vaccine formulation is simpler and does not require complex nanoparticle formulations, but the vaccines are poorly immunogenic and lack sufficient immune response
Solution Approach 1:
The patent uses lipidated imidazoquinoline compounds as intermediary adjuvants that mediate between the simple recombinant protein antigen and the immune system. These compounds activate innate immune receptors (TLR7/TLR8) to enhance the immunogenicity of otherwise weak recombinant protein vaccines, resolving the contradiction between formulation simplicity and immune response adequacy.
Solution Approach 2:
The invention creates a composite vaccine formulation combining recombinant protein antigen with lipidated imidazoquinoline adjuvants. This composite approach merges the simplicity of protein-based vaccines with the immunostimulatory properties of lipidated compounds, achieving both ease of manufacture and sufficient immunogenicity.
2Reliability
If TLR7/8 agonists like imidazoquinoline are used to enhance immune response, then the immune response is enhanced, but the compounds cause rapid systemic dissemination and unwanted immune activation
Solution Approach 1:
The lipidated imidazoquinoline compounds exhibit local quality by being designed to concentrate at the injection site and in lymphatic tissues where they can locally activate immune responses. The lipid modification enables the compounds to associate with cell membranes and accumulate in specific immune compartments, providing localized immune enhancement without widespread systemic activation.
Solution Approach 2:
The invention modifies the physical-chemical parameters of imidazoquinoline compounds by adding lipid groups, which fundamentally changes their pharmacokinetic properties. This parameter change (from water-soluble to lipid-soluble) reduces rapid systemic dissemination while maintaining or enhancing local immunostimulatory activity at the injection site and lymph nodes.
3Reliability
If lipidated imidazoquinoline compounds are used as adjuvants, then the immune response is enhanced and protection against viral infection is increased, but the compound structure becomes more complex
Solution Approach 1:
The patent systematically varies parameters of the lipidated imidazoquinoline structure (lipid chain length, PEG spacer length, imidazoquinoline substitutions) to optimize the balance between immunogenicity and structural complexity. By adjusting these parameters, the invention achieves effective protective immunity while maintaining manufacturability and avoiding excessive structural complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
IMDQ-PEG-CHOL effectively induces robust humoral and cellular immune responses, providing enhanced protection against viral infections by increasing antibody titers and CD4+/CD8+ T-cell immunological memory, while minimizing systemic immune activation.
Implementation Method 1
lipidated imidazoquinoline compounds, such as IMDQ-PEG-CHOL, which are conjugated to cholesteryl-poly(ethylene glycol) to enhance immune response by targeting lymphatic transportation
Data Source
AI summary
Provided herein are lipidated imidazoquinoline compounds and compositions comprising such compounds. The lipidated imidazoquinoline compounds may be used as an adjuvant to enhance to immune response elicited by an antigen of interest. Accordingly, also provided herein are methods for enhancing the immune response of an antigen of interest in a subject, comprising administering to the subject an antigen of interest with a lipidated imidazoquinoline compound described herein in an immunogenic composition, or administering to the subject a composition comprising a lipidated imidazoquinoline compound described herein in combination with (e.g., prior to, concurrently, or subsequently) the administration of an immunogenic composition comprising an antigen of interest to the subject.